Univariable and multivariable logistic regression modeling for CR incidence
| Factor . | Univariable analysis . | Multivariable analysis . | |
|---|---|---|---|
| OR . | P value . | P value . | |
| MD Anderson Cancer Center data set* | |||
| miR-10a-5p | 1.33 | .014 | .019 |
| miR-10b-5p | 1.32 | .004 | .117 |
| NPM1 mutation | 10.50 | <.001 | .005 |
| Age | 0.94 | .032 | .115 |
| Unfavorable PG† | 0.16 | .013 | .221 |
| CN-AML | 7.36 | .001 | .704 |
| CALGB/ALLIANCE data set‡ | |||
| miR-10a-5p | 1.06 | .23 | .01§ |
| NPM1 mutation | 3.68 | <.001 | |
| miR-10b-5p | 1.08 | .18 | .92 |
| BAALC expression | 0.18 | <.001 | .001 |
| Factor . | Univariable analysis . | Multivariable analysis . | |
|---|---|---|---|
| OR . | P value . | P value . | |
| MD Anderson Cancer Center data set* | |||
| miR-10a-5p | 1.33 | .014 | .019 |
| miR-10b-5p | 1.32 | .004 | .117 |
| NPM1 mutation | 10.50 | <.001 | .005 |
| Age | 0.94 | .032 | .115 |
| Unfavorable PG† | 0.16 | .013 | .221 |
| CN-AML | 7.36 | .001 | .704 |
| CALGB/ALLIANCE data set‡ | |||
| miR-10a-5p | 1.06 | .23 | .01§ |
| NPM1 mutation | 3.68 | <.001 | |
| miR-10b-5p | 1.08 | .18 | .92 |
| BAALC expression | 0.18 | <.001 | .001 |
BAALC, brain and acute leukemia cytoplasmic; OR, odds ratio; PG, prognostic group.
Cytogenetically heterogeneous de novo adult AML patients (n = 54). All patients were treated with idarubicin 12 mg/m2 daily on days 1 to 3 and cytarabine 1500 mg/m2 continuous infusion for 4 days.
Unfavorable cytogenetic prognostic group defined by the presence of complex karyotype [≥3 cytogenetic abnormalities excluding t(15;17), t(8;21), or inv16 cases], −7, −5, t(6;9), and inv3 cases.
Older (≥60 years) de novo CN-AML patients (n = 183). Multivariable logistic regression models for the CALGB/ALLIANCE data set were constructed to analyze factors related to the probability of achieving CR using a limited backward-selection procedure.
Interaction.